Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5No longer available 2Available 2Approved for marketing 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroblastoma 2Pheochromocytoma 1Ganglioneuroblastoma 1

Interventions

gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 2belzutifan 2Fluorodeoxyglucose F18 23-fluorobenzylguanidine 2olaparib 1fluorodopa F 18 1fludarabine phosphate 1Specimen Handling 1Phenoxybenzamine 1Magnetic Resonance Spectroscopy 1Interleukin-13 1Genetic Testing 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 16-fluorodopamine 13-Iodobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pheochromocytoma × 3-Iodobenzylguanidine × Clear all
NCT00107289 2026-05-29

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
200 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡